Articles

CAR-T cells: New developments and implications in lymphoma

BJH - 2021, issue 2, march 2021

G. Crochet MD, E. Collinge MD, H. Vellemans MD, A. Bosly MD, PhD, M. André MD, PhD

SUMMARY

Recently, the use of chimeric antigen receptor modified T cells or CAR-T cells has emerged in the therapeutic arsenal of several hematological pathologies, including lymphoma. These CAR-T cells are the product of extensive research on understanding the mechanisms of tumour immunity and are the product of cellular engineering. By combining the specific recognition of an antibody and the activation pathways of a cytotoxic cell, CAR-T cells allow promising clinical results, but they also see the occurrence of side effects that are more specific to these treatments, which it is essential to manage in a multidisciplinary team. Different CAR-T cells are currently available, particularly in diffuse large cell B lymphoma. The trials that have enabled their use differ on many points, including patient selection, the manufacture of the CAR or the pre-therapeutic conditioning. In the future, the use of this expensive therapy could be extended to other lymphomas and new generations of CAR-T cells could emerge.

(BELG J HEMATOL 2020;12(2):77-84)

Read more

P.46 Hepatitis E management in allogeneic Hematopoietic Stem Cell Transplant (HSCT) recipients: a case report

BJH - volume 11, issue Abstract Book BHS, february 2020

G. Crochet MD, M. Bourgeois , E. Collinge MD, H. Vellemans MD, M. André MD, PhD, A. Sonet MD, C. Graux MD, PhD

Read more

PP.07 Blood products and Hematopoietic Progenitor Cells (HPC) Hepatitis E screening: current European practices and guidelines

BJH - volume 11, issue Abstract Book BHS, february 2020

Marc Bourgeois , Nathalie Ausselet , A. Marot , Elodie Collinge , Julien Depaus , Bérangère Devalet , H. Vellemans MD, Anne Sonet , G. Crochet MD, Marc André , Florence Desquesnes , Carlos Graux

Read more